Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

2.

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.

Li J, Zheng J, Wang S, Lau HK, Fathi A, Wang Q.

Front Physiol. 2017 Jan 30;8:15. doi: 10.3389/fphys.2017.00015. eCollection 2017. Review.

3.

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.

Petersen KE, Rakipovski G, Raun K, Lykkesfeldt J.

Curr Diabetes Rev. 2016;12(4):331-358. Review.

4.

GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop.

Giacco F, Du X, Carratú A, Gerfen GJ, D'Apolito M, Giardino I, Rasola A, Marin O, Divakaruni AS, Murphy AN, Shah MS, Brownlee M.

Diabetes. 2015 Sep;64(9):3273-84. doi: 10.2337/db15-0084.

5.

Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells.

Kang MY, Oh TJ, Cho YM.

Endocrinol Metab (Seoul). 2015 Jun;30(2):216-20. doi: 10.3803/EnM.2015.30.2.216.

6.

Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets.

Huang C, Yuan L, Cao S.

Int J Mol Med. 2015 Jul;36(1):173-85. doi: 10.3892/ijmm.2015.2207. Epub 2015 May 12.

7.

GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice.

Tomas E, Stanojevic V, McManus K, Khatri A, Everill P, Bachovchin WW, Habener JF.

Diabetes. 2015 Jul;64(7):2409-19. doi: 10.2337/db14-1708. Epub 2015 Apr 9.

8.

GLP-1(28-36)amide, a Long Ignored Peptide Revisited.

Zhou B, Ji K, Peng A, Yang X, Huang K.

Open Biochem J. 2014 Dec 31;8:107-11. doi: 10.2174/1874091X01408010107. eCollection 2014.

9.

Thirty years of intracrinology.

Re RN.

Ochsner J. 2014 Winter;14(4):673-80. Review.

10.

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.

DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, Qin G, Zhuang S, Zhao TC.

Am J Physiol Endocrinol Metab. 2014 Oct 15;307(8):E630-43. doi: 10.1152/ajpendo.00109.2014. Epub 2014 Aug 12.

11.

GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

Taing MW, Rose FJ, Whitehead JP.

Drug Des Devel Ther. 2014 Jun 3;8:677-88. doi: 10.2147/DDDT.S35723. eCollection 2014. Review.

12.

GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs.

Elahi D, Angeli FS, Vakilipour A, Carlson OD, Tomas E, Egan JM, Habener JF, Shannon RP.

Peptides. 2014 Sep;59:20-4. doi: 10.1016/j.peptides.2014.06.004. Epub 2014 Jun 14.

13.

Fungicidal drugs induce a common oxidative-damage cellular death pathway.

Belenky P, Camacho D, Collins JJ.

Cell Rep. 2013 Feb 21;3(2):350-8. doi: 10.1016/j.celrep.2012.12.021. Epub 2013 Feb 14.

15.

Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.

Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E.

J Neurosci. 2012 Oct 3;32(40):13701-8. doi: 10.1523/JNEUROSCI.2107-12.2012.

16.

The role of the Wnt signaling pathway in incretin hormone production and function.

Chiang YT, Ip W, Jin T.

Front Physiol. 2012 Jul 12;3:273. doi: 10.3389/fphys.2012.00273. eCollection 2012.

17.

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity.

Liu Z, Stanojevic V, Brindamour LJ, Habener JF.

J Endocrinol. 2012 May;213(2):143-54. doi: 10.1530/JOE-11-0328. Epub 2012 Mar 13.

18.

Cardiovascular biology of the incretin system.

Ussher JR, Drucker DJ.

Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8. Review.

19.

Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.

Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, Holz GG.

Prog Biophys Mol Biol. 2011 Nov;107(2):236-47. doi: 10.1016/j.pbiomolbio.2011.07.005. Epub 2011 Jul 19. Review.

20.

GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Roth JD, Erickson MR, Chen S, Parkes DG.

Br J Pharmacol. 2012 May;166(1):121-36. doi: 10.1111/j.1476-5381.2011.01537.x. Review.

Supplemental Content

Support Center